3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
12
Phase NA
9
Phase 2
8
Phase 3
2
Phase EARLY_PHASE1
1
Status
Unknown
3
Recruiting
3
Terminated
2
Active not recruiting
2
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Conditions
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Interventions
Cisplatin
62
Carboplatin
52
Paclitaxel
48
Radiotherapy
47
Docetaxel
41
Gemcitabine
38
Cyclophosphamide
36
Rituximab
33
Capecitabine
28
Fluorouracil
27
Dexamethasone
27
Doxorubicin
26
Prednisone
21
Bevacizumab
20
Pemetrexed
19
Oxaliplatin
18
Leucovorin
18
pembrolizumab
17
Vincristine
17
Etoposide
17
Cytarabine
15
Drug Therapy
14
Irinotecan
13
Imatinib Mesylate
13
Filgrastim
13
Zoledronic Acid
12
Radiosurgery
12
Erlotinib Hydrochloride
12
Trastuzumab
11
Goserelin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Terminated
×
Fluorodeoxyglucose F18
×
Clear all
NCT06125028
2026-04-28
LYMFOR
Pentixapharm AG
Phase 3
Terminated
8 enrolled
NCT00522639
2009-06-30
FDG-PET lung
Maastricht Radiation Oncology
Phase 3
Terminated
120 enrolled